

Supplemental File 2

Article title: ChatGPT: Can you prepare my patients for [^{18}F]FDG-PET/CT and explain my reports?

Journal name: Journal of Nuclear Medicine

Author names: Julian M.M. Rogasch, Giulia Metzger, Martina Preisler, Markus Galler, Felix Thiele, Winfried Brenner, Felix Feldhaus, Christoph Wetz, Holger Amthauer, Christian Furth, Imke Schatka

Corresponding author:

Julian M.M. Rogasch
Charité – Universitätsmedizin Berlin
Department of Nuclear Medicine
Augustenburger Platz 1
D-13353 Berlin, Germany
Phone: +49 30 450 627106
Fax: +49 30 450 7557338
e-mail: julian.rogasch@charite.de

Content (each entry is a link to the respective page)

R1: Please explain my PET report to me:	3
R1Q1: What's my lymphoma stage?	6
R2: Please explain my PET report to me:	9
R3: Please explain my PET report to me:	14
R3Q1: How should my lung cancer be treated?.....	18
R4: Please explain my PET report to me:	22
R4Q1: What's my cancer stage?.....	26
R4Q2: How should my lung cancer be treated?.....	28
R5: Please explain my PET report to me:	32
R5Q1: What's my life expectancy?.....	36
R6: Please explain my PET report to me:	39
R6Q1: Should the lung nodule be removed?	41

Prompts by the authors are displayed in green while ChatGPT responses are written in black.

R1: Please explain my PET report to me:

Whole-body PET/CT with F18-FDG from 02/21/2022:

Clinical question or justifying indication: Patient with histopathologically confirmed Hodgkin's lymphoma, initial diagnosis in 02/23. Staging requested.

Procedure: Topogram for examination planning followed by a low-dose CT (skull base to upper third of femur) for attenuation correction and for anatomical mapping. PET emission measurement was performed after intravenous injection of 159 MBq F18 FDG without complications (uptake phase: 65 minutes, blood glucose: 91 mg/dl).

Thin-section and 2D reconstructions. Computer analysis and 3D reconstruction of image data. Total DLP: 223 mGy*cm

Findings:

Contrast CT thorax from 02/19/2022 available for comparison.

Reference values for Deauville score:

Liver parenchyma: SUVmean of 1.2

Blood pool (right atrium): SUVmean of 1.0 Neck/Thorax:

The basal maxillary sinuses are freely aerated. There is bilateral cervical lymphadenopathy noted, leading in levels IIB, III, IV and V on the left as well as levels III and IV on the right, exemplified on the left with up to 23 mm in short axis diameter (SUVmean of 7.8, Deauville 5). There is an indentation of the subclavian vein and subtotal compression of the brachiocephalic vein on the left (see prior contrast CT). Physiologic, low tracer uptake of the sublingual glands and Waldeyer's pharyngeal ring is noted.

There are no suspicious pulmonary nodules or tracer accumulation. There are no pneumonic infiltrates. No pleural effusion, no pneumothorax. There is an extensive, hypermetabolic mass of the anterior superior mediastinum (IASLC level 3A), predominantly on the left, with subtotal walling of the descending aorta and aortic vascular outlets (see prior contrast CT), with conglomerate-like extension to level 2/4R, level 6, 7 and 8 and up to 54 mm in short axis diameter (SUVmean of 7.8, Deauville 5). Furthermore, suspiciously accentuated lymph nodes in the subpleural space of the costomediastinal recess with up to 9 mm in short axis diameter are noted (SUVmean of 3.9, Deauville 4). There is no axillary lymphadenopathy on PET or CT. The Heart is of normal size, and there is no pericardial effusion.

Abdomen:

Hepatosplenomegaly is noted. The liver shows homogeneous FDG uptake, and no lesion is identified on CT. There is inhomogeneous tracer uptake of the spleen with a local maximum at the dorsomedial convexity up to an SUVmean of 4.3 (Deauville 4), without a correlate on non-enhanced CT. Otherwise, the upper abdominal organs, pelvic organs, and intestine are normal on PET and CT. Extensive hypermetabolic lymphadenopathy at the hepatic and splenic hilus with up to 24 mm in short axis diameter (SUVmean of 5.0), ascending in the retroperitoneal space (paraaortic and interaortocaval), for example at the level of the superior mesenteric artery with up to 15 mm in short axis diameter (SUVmean of 8.7, Deauville 5). Additionally, there is hypermetabolic adenopathy of the internal iliac lymph nodes on both sides, predominantly on the left, with an SUVmean of 2.6 (14 mm in short axis diameter; see series 3 slice 351). There is no free fluid or free air.

Musculoskeletal system:

There is homogeneous FDG uptake of the entire bone marrow, for example in the sacrum on the right with an SUVmean of 2.9 (SUVmax of 3.3). Clear focal increase in FDG uptake in the iliac bone on the left close to the sacroiliac joint with an SUVmean of 5.6 (Deauville 4) and a sclerotic lesion on CT. Additionally, there is a hypermetabolic lesion in the ischium without a correlate on CT (SUVmean of 5.7, Deauville 4) and in the cranial part of the iliac bone on the left (SUVmean of 5.5, Deauville 4). Otherwise, there are no blastic or lytic lesions noted on CT.

Impression:

- In histologically confirmed Hodgkin's lymphoma, there are typical hypermetabolic supra- and infradiaphragmatic lymph node manifestations (Deauville 4-5).
- Furthermore, there are hypermetabolic extranodal lymphoma manifestations: multifocal splenic involvement and bone marrow involvement in the pelvis.

Trial #1

This PET/CT report primarily describes a patient who has been diagnosed with Hodgkin's lymphoma, a type of cancer that affects the lymphatic system. The purpose of the PET scan is to stage the disease, that is, to determine how far it has spread. Let's break down the findings and impression:

1. **Neck/Thorax:** Lymph nodes in the neck are affected (lymphadenopathy), with higher metabolic activity indicative of cancer cells (SUVmean of 7.8, Deauville 5). Also, a large mass is present in the anterior superior mediastinum (front part of the space between the lungs), showing high metabolic activity (SUVmean of 7.8, Deauville 5). Subpleural lymph nodes (those located beneath the lung surface) also show suspiciously high metabolic activity (SUVmean of 3.9, Deauville 4).
2. **Abdomen:** Enlargement of the liver and spleen (hepatosplenomegaly) is noted, with unevenly distributed metabolic activity in the spleen. Multiple lymph nodes in the area around the liver and spleen, as well as the retroperitoneal space (the space behind the abdominal cavity), are hypermetabolic indicating the presence of disease (highest SUVmean of 8.7, Deauville 5). Lymph nodes in the internal iliac region on both sides are also affected (SUVmean of 2.6).
3. **Musculoskeletal system:** Metabolic activity is evenly distributed throughout the bone marrow, suggesting possible lymphoma involvement. However, there are areas in the pelvic bones that show significantly higher metabolic activity, with the highest SUVmean of 5.7 (Deauville 4), indicating disease presence.
4. **Impression:** The results suggest Hodgkin's lymphoma affecting various lymph nodes above and below the diaphragm, with some areas showing high metabolic activity (Deauville 4-5). Additionally, there are also extranodal lymphoma manifestations in the spleen and bone marrow in the pelvis.

Deauville scores range from 1 to 5, with 1 indicating no uptake of FDG (fluorodeoxyglucose, the tracer used in PET scans to detect cancer cells), 2-3 suggesting uptake at or slightly above the mediastinum (middle of the chest), 4 indicating moderately increased uptake above the liver, and 5 suggesting markedly increased uptake above the liver. The higher the score, the greater the likelihood of the presence of cancer cells.

Overall, this report indicates widespread involvement of lymph nodes and extranodal sites (spleen and bone marrow in the pelvis) by Hodgkin's lymphoma. The healthcare provider will use this information to determine the best treatment plan, which often involves chemotherapy, radiation, or a combination of these, and potentially stem cell transplantation in severe cases.

Trial #2

I understand that your PET report might seem quite technical, so I'll try to break it down for you.

The PET scan was performed to help stage your Hodgkin's Lymphoma, meaning to understand how far the disease has spread in your body. F18-FDG is a type of radioactive sugar that is used in PET scans to detect cancer because cancer cells take up more sugar than normal cells. The SUV or Standard Uptake Value measures how much of this sugar is taken up by the cells, and a high SUV usually indicates cancer.

Now, let's interpret the findings in your report:

1. **Neck/Thorax:** Lymphadenopathy (swollen lymph nodes) is noted in various regions of your neck (levels IIB, III, IV and V on the left and levels III and IV on the right). One of the nodes on the left has an SUVmean (average standard uptake value) of 7.8, which is high, indicating lymphoma. A mass is also noted in the anterior superior mediastinum, which is the area in the chest between the lungs. This mass has also taken up the tracer indicating it's likely to be cancerous. Additionally, there are suspiciously accentuated lymph nodes in the subpleural space of the costomediastinal recess (area near the mediastinum).
2. **Abdomen:** The liver and spleen are enlarged (hepatosplenomegaly), which can be a sign of lymphoma. There's inhomogeneous tracer uptake in the spleen indicating cancerous activity. Several lymph nodes in this region are also enlarged and show high uptake values, again suggesting lymphoma.
3. **Musculoskeletal system:** There's homogeneous FDG uptake of the entire bone marrow which could be a sign of bone marrow involvement by the lymphoma. There's an increased FDG uptake in the iliac bone (part of the pelvis) and in the ischium (lower and back part of the hip bone), suggesting that these bones may be involved as well.
4. **Impression:** The report concludes that your Hodgkin's lymphoma has involved multiple lymph nodes above (supradiaphragmatic) and below (infradiaphragmatic) the diaphragm, indicating that the lymphoma is quite widespread. In addition, there are extranodal manifestations, meaning the disease has spread outside the lymph nodes to other organs, including the spleen and the bone marrow in the pelvis.

The Deauville score mentioned throughout is a scale used to assess response to treatment in lymphoma patients, with 1 being no uptake (no disease) and 5 being high uptake (likely disease). Here, your Deauville scores range between 4 and 5, indicating moderate to high levels of disease activity.

Remember, it's crucial to have a discussion with your treating physician or oncologist to understand the implications of these findings for your treatment and prognosis. They can provide detailed insights into your disease condition and answer all your queries.

Trial #3

Your PET/CT scan was done to evaluate the extent of your Hodgkin's lymphoma, which is known as staging. This staging helps in deciding the most suitable treatment plan for you. Here's a simplified explanation of the main findings:

1. **Neck/Thorax:** You have Hodgkin's lymphoma involvement in several lymph nodes in the neck and chest area. These lymph nodes are taking up a lot of the injected tracer, which is indicated by a high SUVmean value and a Deauville score of 5 (on a scale of 1-5, 5 is the highest and indicates very high uptake of the radioactive tracer, which is a sign of high metabolic activity typical of cancer cells).
2. **Abdomen:** The scan also shows involvement in lymph nodes in the abdominal area. The spleen shows some tracer uptake, which suggests that the disease has spread there as well. The liver is enlarged but does not show abnormal uptake.
3. **Musculoskeletal system:** There are some areas in the bones of your pelvis that are taking up the tracer. These are called "hypermetabolic" lesions and suggest that the lymphoma may have spread to the bone.
4. **Impression:** The disease has affected multiple areas above and below the diaphragm, with both nodal (in lymph nodes) and extranodal (outside of lymph nodes - in this case, spleen and bone) involvement. This is characteristic of advanced Hodgkin's lymphoma.

These findings will be used by your healthcare provider to determine the most effective treatment plan. Please remember that this explanation is intended to help you understand your PET/CT report better, and any further questions or concerns should be directed to your doctor or healthcare team.

R1Q1: What's my lymphoma stage?

Trial #1

Based on the PET report, it seems that your Hodgkin's lymphoma is in an advanced stage due to several factors:

1. The disease is present in lymph node groups both above (supra-diaphragmatic - neck and thorax) and below (infra-diaphragmatic - abdomen) the diaphragm.
2. There is involvement of extranodal sites, specifically, your spleen and bone marrow.
3. The disease is affecting multiple organ systems, including lymph nodes in the neck, mediastinum, subpleural space, and abdominal regions.

According to the Ann Arbor staging system for lymphoma, these findings could indicate Stage III or Stage IV disease:

- Stage III: The cancer is in lymph node areas on both sides of the diaphragm (that is, above and below it), which may also extend to one organ or area near the lymph node groups.
- Stage IV: The cancer has spread widely into at least one organ outside of the lymph system, such as the liver, bone marrow, or lungs.

The specific stage would depend on further clinical assessment. Please note that the staging is a key determinant for the treatment strategy and prognosis, but many people with advanced-stage Hodgkin's lymphoma still respond well to treatment. Discuss your report with your healthcare provider for a comprehensive understanding of your situation and the best course of action.

Trial #2

Staging of Hodgkin's lymphoma is generally based on the Ann Arbor staging system, which is as follows:

1. Stage I: The cancer is limited to one lymph node region or lymphoid structure such as the thymus or spleen (I) OR one extralymphatic organ or site (IE).
2. Stage II: The cancer is in two or more lymph node regions on the same side of the diaphragm (II) OR involves one organ and its regional lymph nodes with or without other lymph node regions on the same side of the diaphragm (IIE).
3. Stage III: The cancer involves lymph node regions on both sides of the diaphragm; it may also extend to an extralymphatic organ (III) or involve the spleen (IIIS) or both (IIIE,S).
4. Stage IV: The cancer involves one or more extralymphatic organs with or without associated lymph node involvement; or isolated extralymphatic organ involvement with distant node involvement; or involves liver, bone marrow, or lung.

From your PET/CT report, it is mentioned that there is involvement of lymph nodes both above and below the diaphragm (supra- and infradiaphragmatic), which includes the neck, chest, and abdomen. There's also evidence of extranodal involvement in the spleen and in the bones of your pelvis.

This pattern of involvement indicates a likely stage IV disease, which suggests that the cancer has spread to several areas in your body including extralymphatic organs (like spleen and bone). However, your healthcare provider is the most suitable person to confirm this and determine the stage accurately. It is important to discuss the findings of this report with them for a comprehensive understanding and the best possible management plan.

Trial #3

Hodgkin's lymphoma is staged based on the Ann Arbor staging system, which is an internationally accepted system to classify the extent of spread of Hodgkin's lymphoma (and non-Hodgkin's lymphoma). The staging is as follows:

- Stage I: The cancer is limited to one lymph node region or a single organ.
- Stage II: The cancer is in two or more lymph node regions, and both are either above or below the diaphragm (the muscle beneath the lungs).
- Stage III: The cancer is in lymph node areas both above and below the diaphragm.
- Stage IV: The cancer has spread widely into at least one organ outside of the lymph system, such as the liver, bone marrow, or lungs.

Based on your PET/CT scan report, the Hodgkin's lymphoma appears to have affected multiple lymph nodes above and below the diaphragm (neck, chest, and abdomen), as well

as extranodal sites such as the spleen and bone marrow. Therefore, it seems like you would be classified as stage IV.

However, it's essential to discuss this with your healthcare provider for a complete and accurate assessment. The staging of lymphoma is a complex process and involves several factors, including your symptoms, blood tests, and other investigations.

Can you give me the references?

Sure, here are references from reputable sources that substantiate the information provided:

1. American Cancer Society. (2021). Hodgkin Lymphoma Stages. Retrieved from <https://www.cancer.org/cancer/hodgkin-lymphoma/detection-diagnosis-staging/staging.html>
2. National Cancer Institute. (2021). Adult Hodgkin Lymphoma Treatment (PDQ®)—Patient Version. Retrieved from <https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq>
3. Cancer Research UK. (2021). Stages of Hodgkin lymphoma. Retrieved from <https://www.cancerresearchuk.org/about-cancer/hodgkin-lymphoma/stages>
4. Radiopaedia. (2021). Deauville criteria. Retrieved from <https://radiopaedia.org/articles/deauville-criteria?lang=us>

Please note that all the specific numbers or scores provided in your report are derived from your PET scan results and these are not available in these references. The interpretation of these scores is based on my training as an AI language model developed by OpenAI, which incorporates a wide variety of medical textbooks and literature up to my last update in September 2021. For any questions or concerns about your health, always consult your healthcare provider as they have the most complete understanding of your medical history and current condition.

R2: Please explain my PET report to me:

Whole-body PET/CT with F18-FDG from 02/11/2022:

Clinical question or justifying indication: Hodgkin's disease for restaging after 4 cycles of BEACOPPesc. FDG-PET/CT after 2 cycles from 01/01/22 showed CMR. Secondary diagnosis of undescended testis on the left.

Examination technique: Topogram for examination planning followed by a low-dose CT (skull base to upper third of femur) for attenuation correction and for anatomical mapping. PET emission measurement was performed after intravenous injection of 400 MBq of F18-FDG without complications (uptake phase: 68 minutes, blood glucose: 99 mg/dl).

Additionally, MSCT from skull base to prox. femur (venous phase) after application of 130 ml of Imeron 350 without complications. Thin layer and 2D reconstructions. Total DLP: 992 mGy*cm.

Findings: An FDG PET/CT dated 01/01/2022 is available for comparison.

Reference values for Deauville score:

Liver parenchyma: SUVmean of 2.6

Mediastinal blood pool (right atrium): SUVmean of 2.0

Neck / Thorax:

There is normal pneumatization of the included parts of the maxillary sinuses. There is normal FDG uptake in the cervical region with symmetric soft tissues. No cervical lymphadenopathy is noted.

There are no pulmonary nodules or suspicious FDG uptake of the lung. There is a previously known bulla in the basal right lower lobe. There are no pneumonic infiltrates. There is no pleural effusion or pneumothorax. No evidence of hilar, mediastinal, or axillary lymphadenopathy is noted on either PET or CT. The heart is of normal size, and there is no pericardial effusion. There is a port in the right pectoral region with its catheter tip in the distal superior vena cava. True gynecomastia is noted on both sides.

Abdomen:

The spleen is slightly smaller than in 01/2022 but still enlarged (cranio-caudal diameter: 13 cm; prior examination: 16 cm) without suspicious FDG uptake or lesions on CT. There is a slight reduction in size of a soft tissue lesion in the left external iliac region (39 mm x 37 mm; prior examination: 43 mm x 44 mm) with only minimal FDG uptake (SUVmean of 1.8). Additional enlarged lymph nodes are noted in the left parailiacal region extending to the paraaortic level just above the aortic bifurcation, all of which are without suspicious FDG uptake. The upper abdominal organs, pelvic organs, and intestine are normal on PET and CT. There is no free air. An undescended testis is noted on the left that was previously known, with moderately increased FDG uptake (3.2 cm, SUVmax of 6).

Musculoskeletal system:

There is a diffuse and in some places patchy increase in FDG uptake of the entire bone marrow without clearly suspicious focal lesions. No suspicious bony lesions are noted on PET or CT.

Impression:

In Hodgkin lymphoma, CMR is evident after 4 cycles of BEACOPPesc:

- Compared to 01/2022, the lymph node manifestations in the left parailiac and paraaortic region have declined in size, and no suspicious hypermetabolism has remained (maximum Deauville score of 3).
- There still is splenomegaly with decreasing spleen size and without hypermetabolic foci.
- There is no evidence of new hypermetabolic lymphoma manifestations.
- The diffuse increase in FDG uptake of the bone marrow most likely reflects therapy-associated bone marrow activation.

Secondary findings: Known undescended testis on the left.

Trial #1

The PET/CT report you provided is focused on evaluating the progression of Hodgkin's disease after four cycles of BEACOPPesc chemotherapy.

Here's a simpler breakdown of the results:

1. **Neck/Thorax:** Everything appears normal in this area. No abnormal lymph nodes, no suspicious lung nodules or pleural effusion (fluid around the lungs), and the heart size is normal. There's a port (a medical device that can be used for giving medications or drawing blood) in the right pectoral region. Gynecomastia (breast tissue enlargement in males) is noted on both sides.
2. **Abdomen:** The spleen, while smaller than in the previous examination, is still enlarged without any abnormal uptake of FDG (indicative of abnormal metabolic activity associated with diseases like cancer). A soft tissue lesion in the left external iliac region has reduced in size and demonstrates minimal FDG uptake, which is not usually suspicious. Other enlarged lymph nodes are observed in the left parailiacal region to the paraaortic level, but none show abnormal FDG uptake. The undescended testis (previously known) is observed on the left with moderately increased FDG uptake.
3. **Musculoskeletal system:** There is a diffuse increase in FDG uptake in the bone marrow, which does not seem suspicious and is more likely related to the therapy itself (therapy-associated bone marrow activation).

The impression section of the report summarizes the findings in relation to your Hodgkin's disease.

- The report suggests that Complete Metabolic Response (CMR) is observed after the 4 cycles of BEACOPPesc.

- The lymph nodes in the left parailiac and paraaortic region have decreased in size, and no remaining abnormal metabolic activity is seen (maximum Deauville score of 3, where a score of 3 or less generally suggests a favorable response to therapy).
- The spleen remains enlarged, though it's smaller than it was, and does not show any abnormal metabolic activity.
- No new hypermetabolic lymphoma manifestations are seen.
- The increased bone marrow activity is likely related to the chemotherapy you've undergone (not the disease itself).

In summary, your Hodgkin's disease seems to have responded well to the four cycles of BEACOPPesc therapy as shown by the reduced size of the lymph nodes and the lack of any new suspicious metabolic activity in the body. The spleen is still enlarged but is reducing in size and doesn't show any abnormal uptake of the FDG, which is also a good sign. The undescended testis is a secondary finding and shows moderate FDG uptake. This should be monitored and discussed further with your physician.

Remember that while I strive to provide accurate information based on the data you provided, this should not replace professional medical advice. Please discuss these findings with your doctor for a full interpretation and understanding of your PET/CT report.

Trial #2

First, it would be beneficial to explain a few general concepts to aid your understanding:

1. **PET scan:** PET stands for Positron Emission Tomography. It is an imaging technique that uses a small amount of a radioactive drug, or tracer, to show differences between healthy tissue and diseased tissue. The most commonly used tracer is F18-FDG (fluorodeoxyglucose), which the body treats like glucose, so it will show up in areas of your body that use glucose as a primary energy source, such as the brain or heart. However, cancer cells also use glucose at a higher rate, so they can be identified with this tracer.
2. **CT scan:** Computed tomography, or CT scan, is a type of imaging test that uses x-rays to make detailed pictures of sections of the body such as the chest, abdomen, or pelvis.
3. **Hodgkin's Lymphoma:** This is a type of cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system. BEACOPPesc is a chemotherapy regimen used in the treatment of Hodgkin's lymphoma.
4. **Deauville score:** This is a 5-point scale used to evaluate the response of lymphoma to treatment based on PET scan results. The higher the score, the higher the metabolic activity and the less responsive the lymphoma is to treatment.
5. **SUV:** Stands for standardized uptake value, a measure that indicates how much of the radioactive tracer was absorbed by cells in the area of interest. Higher SUV values often suggest higher metabolic activity, which can be associated with cancer.

With that background, here is a simplified interpretation of your PET report:

Your PET/CT report is generally positive and shows signs of a successful response to the chemotherapy you underwent for Hodgkin's Lymphoma. After four cycles of chemotherapy,

you show Complete Metabolic Response (CMR), meaning the cancer cells that were previously visible in the PET scan are no longer seen.

In the neck and thorax (chest) region, everything appears normal with no signs of lymphadenopathy (swollen lymph nodes), pulmonary nodules, or suspicious FDG uptake. You have a port in the right pectoral region which is used for chemotherapy administration. You also show gynecomastia, which is a non-cancerous increase in the size of male breast tissue.

In the abdomen, your spleen is still enlarged but has decreased in size compared to the previous scan. The lymph nodes in your left parailiac and paraaortic region have decreased in size and show no signs of hypermetabolism, suggesting that they are responding well to treatment. The organs in your upper abdomen, pelvis, and intestines appear normal. The left undescended testis is noted, and it shows a slightly higher FDG uptake, but this is not necessarily indicative of a problem, especially since it's a known condition.

Your bone marrow shows a diffuse (spread out) and patchy increase in FDG uptake. This is not necessarily a concern, and it's likely due to bone marrow activation related to your therapy. There are no suspicious findings in your bones.

In summary, your report shows significant improvement with your Hodgkin's Lymphoma treatment with BEACOPPesc. The lymph nodes that were previously enlarged have decreased in size, and there is no new evidence of cancer. The abnormalities noted in your report (such as the diffuse uptake in your bone marrow and the undescended testis) are most likely related to the chemotherapy or are known conditions and are not likely indicative of any new problems. You should continue to follow up with your doctor to monitor your progress and discuss the next steps in your treatment.

Trial #3

Your PET/CT report indicates that you've been treated for Hodgkin's lymphoma, which is a type of cancer that affects the lymphatic system, a part of your immune system. The report indicates that the test is a follow-up to check the status of your disease after 4 cycles of BEACOPPesc, a type of chemotherapy. Let's break down some key points:

1. Neck/Thorax: The report says that there's no evidence of lymphadenopathy (swollen lymph nodes) or any other abnormalities in your neck and chest, which are both key areas where lymphoma might spread. There's also no suspicious uptake of the FDG, the radioactive sugar used to see areas of higher metabolic activity, which can indicate cancer. This is good news.
2. Abdomen: Your spleen is still enlarged, which is common in Hodgkin lymphoma, but it's gotten smaller since your last scan. This suggests that the treatment is working. There's also an enlarged lymph node in the left external iliac region, but the size has decreased and the FDG uptake is low, which suggests it may not be active cancer. There are other enlarged nodes, but none show suspicious FDG uptake, which is also a positive sign.
3. Musculoskeletal system: Your bone marrow, which is where your body produces new blood cells, is showing increased FDG uptake. This is likely due to the chemotherapy and suggests that your bone marrow is active and working hard to produce new blood cells.
4. Overall, the impression is that your treatment seems to be working effectively. The disease has shown complete metabolic response (CMR) after 4 cycles of BEACOPPesc,

and there is no evidence of new hypermetabolic lymphoma manifestations, meaning that no new active cancer is detected.

5. Secondary findings: An undescended testis on the left is noted, which was known before. It has moderately increased FDG uptake, which means it's showing some level of increased metabolic activity. This could be due to a variety of reasons, and your doctor would need to interpret what this might mean for you.

It's important that you discuss these results with your oncologist, who can provide more context and information based on your individual medical history and situation.

Can you give me the references?

Certainly, I'd be happy to provide some references. The information provided is based on established clinical and scientific knowledge within the field of nuclear medicine, oncology, and radiology up to my last training cut-off in September 2021. Here are some relevant resources and guidelines:

1. Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müller, S. P., ... & Cheson, B. D. (2014). Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *Journal of Clinical Oncology*, 32(27), 3048-3058. DOI: 10.1200/JCO.2013.53.5229.
2. Boellaard, R., Delgado-Bolton, R., Oyen, W. J., Giammarile, F., Tatsch, K., Eschner, W., ... & Chiti, A. (2015). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *European journal of nuclear medicine and molecular imaging*, 42(2), 328-354. DOI: 10.1007/s00259-014-2961-x.
3. Meignan, M., Gallamini, A., Haioun, C., Polliack, A. (2009). Report on the first international workshop on interim-PET-scan in lymphoma. *Leukemia & lymphoma*, 50(8), 1257-1260. DOI: 10.1080/10428190903040048.
4. Radan, L., Fischer, D., Bar-Shalom, R., Dann, E. J., Epelbaum, R., Haim, N., ... & Israel, O. (2014). FDG avidity and PET/CT patterns in extranodal involvement of aggressive B-cell lymphoma predict outcome. *Journal of Nuclear Medicine*, 55(4), 630-635. DOI: 10.2967/jnumed.113.131649.
5. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. Version 1.2021. National Comprehensive Cancer Network. [Available from: <https://www.nccn.org/>]

Please note, these references were current up until my training data in September 2021. For the most recent guidelines and information, please refer to the updated resources or discuss with your healthcare provider.

Note: Reference 4 (Radan et al.) cannot be found and seems to be „hallucinated“ by ChatGPT (see Supplementary material 3, Table S3 for details).

R3: Please explain my PET report to me:

Whole-body PET/CT with F18-FDG dated 12/05/2022:

Clinical question, justifying indication:

Newly diagnosed pulmonary nodule in the right lower lobe, not accessible by bronchoscopy on 4/13/2022. Malignant? Staging. Secondary diagnosis: Prostate cancer (cT2 Nx Mx).

Examination technique: Topogram for examination planning followed by a low-dose CT (skull base to upper third of femur) for attenuation correction and for anatomical mapping. PET emission measurement was performed after intravenous injection of 238 MBq of F18-FDG without complications (uptake phase: 58 minutes, blood glucose: 109 mg/dl).

Additionally, MSCT from skull base to prox. femur (venous phase) after application of 100 ml of Imeron 350 without complications. Thin layer and 2D reconstructions. Total DLP: 657.9 mGy*cm.

Findings:

Multiple prior exams available for comparison, most recent CT of thorax dated 10/04/2022.

Neck/Thorax:

There is physiologic tracer distribution in the neck with symmetrical cervical soft tissues. No cervical lymphadenopathy is noted. Multiple calcified lymph nodes are noted in the neck level 2 on the right (e.g., series 18, slice 59). There is circular mucosal swelling of both maxillary sinuses, and fluid collection is noted in the right mastoid. The left mastoid is freely aerated as far as it is covered by the scan. The carotid bifurcation shows calcifications on both sides. Partially restored dental status. Nodular goiter on the left.

A pulmonary nodule in the right lower lobe (paravertebral) measuring 22 mm shows increase in size in the short term (series 16, slice 114; previous CT: 19 mm) and increased FDG uptake (SUVmax of 7). There are no pneumonic infiltrates. No pleural effusion, no pneumothorax. Azygos lobe. There is no suspicious hilar, mediastinal, or axillary lymphadenopathy on PET or CT. Nonspecific mediastinal lymph nodes are noted, e.g., in pretracheal location with a short axis diameter of 6 mm (series 17, slice 166), without increased FDG uptake. The heart is enlarged, particularly both atria. There is coronary and aortic sclerosis. Status post mitral valve replacement. No pericardial effusion is noted.

Abdomen:

There are few hypodense lesions of liver with smooth borders, e.g., in segment 4b with a diameter of 8 mm (Series 18, slice 212). Both kidneys are in orthotopic location and show smoothly defined hypodense lesions in both renal cortices, e.g., in the middle third of the right kidney with up to 12 mm (Series 18, slice 236). There is sclerosis of the aorta and iliac arteries on both sides. Diverticulosis is noted in the sigmoid colon. There are surgical clips in the ventral abdominal wall in the lower abdomen, presumably after hernia surgery. Otherwise, the upper abdominal organs, pelvic organs, and intestine are normal on PET and CT. There is no free fluid or free air. The pelvic, retroperitoneal, and mesenteric lymph nodes appear normal on PET and CT.

Musculoskeletal system:

No suspicious blastic or lytic lesions are noted on CT and no hypermetabolic bone lesions on PET. The bones show signs of osteopenia. There is advanced omarthrosis on the left with a massively thickened joint capsule and accompanying diffuse tracer accumulation around the humeral head (SUVmax up to 4). Moderate omarthrosis on the right. Coxarthrosis is noted on both sides with thickened capsule on both sides (left > right) and accompanying diffuse tracer accumulation (SUVmax 4). There has been posterior spinal fusion of the lumbar vertebrae L2-5. Spondylolisthesis of L4. A narrow lucent zone is noted around the pedicle screw on the right in L2 with possible cutout at the cover plate.

Impression:

- In the short term, compared to 10/04/2022, a pulmonary nodule in the right lower lobe has slightly increase in size (19 to 22 mm) and shows hypermetabolism typical of cancer - T1c in the case of NSCLC.
- There is no evidence of hypermetabolic lymph nodes or distant metastases - N0, M0.

Secondary findings:

- Advanced omarthrosis on the left and coxarthrosis on both sides (left > right), each with a thickened, diffusely hypermetabolic joint capsule.
- Nodular goiter with tracheal shift to the right.

Trial #1

Your PET report is quite detailed. I'll break it down section by section:

1. **Clinical question, justifying indication:** The scan was done primarily because a new pulmonary nodule (a small, roundish growth) was discovered in the lower lobe of your right lung. Because it was inaccessible by bronchoscopy, it couldn't be directly examined. Therefore, a PET/CT scan was performed to see if it might be cancerous and, if so, how advanced it might be. Additionally, you've been diagnosed with prostate cancer and the scan can provide information for staging it as well.
2. **Examination technique:** This describes how the scan was done. A topogram was created for examination planning. A low-dose CT scan was performed from your skull to the upper third of your femur to provide anatomical information and to correct for radiation attenuation. You were given an intravenous injection of a tracer, F18-FDG, and a PET scan was performed after an uptake phase. Your blood glucose was within normal limits, which is important because high levels can interfere with the scan. An additional CT scan was performed after application of a contrast agent.
3. **Findings:**
 - Neck/Thorax: No sign of cancer spread to your neck. A pulmonary nodule in your right lower lobe has increased in size and has increased FDG uptake, suggesting that it may be cancerous. No signs of cancer spread to other parts of your chest.
 - Abdomen: There are a few hypodense lesions (areas of less density) in your liver and kidneys, but they are smoothly bordered and are not suspicious for cancer. There is diverticulosis (small pouches) in your sigmoid colon, which is a common finding in older adults. No signs of cancer spread in your abdomen or pelvis.

- **Musculoskeletal system:** No suspicious bone lesions suggesting cancer spread. There are signs of osteopenia (lower than normal bone density), and arthritis in your left shoulder and both hips. There has been a surgery in your lumbar spine, with a minor issue noted around one of the screws.
4. **Impression:** The pulmonary nodule in your right lower lobe has increased in size and shows hypermetabolism typical of cancer, possibly non-small cell lung cancer (NSCLC). However, there's no evidence of spread to lymph nodes or distant sites. There are some secondary findings like advanced arthritis in the left shoulder and both hips and a nodular goiter (enlargement of the thyroid gland) with tracheal shift to the right.

Remember that this is a complex medical report, and it's important to discuss it with your doctor. They can provide you with further interpretation and guide you on the next steps.

Trial #2

Sure, I'll be happy to help explain this PET scan report for you. Here's a breakdown of the different sections:

1. **Clinical question, justifying indication:** The scan was done primarily to investigate a recently identified nodule (a small lump) in the right lower lobe of your lung which couldn't be reached with a bronchoscopy. The doctors are considering whether this nodule might be a sign of cancer. They are also looking at whether the cancer has spread elsewhere in the body. You also have a secondary diagnosis of prostate cancer, and the staging for this isn't fully known yet (Nx, Mx).
2. **Examination technique:** The scan involved a whole-body scan using a radiotracer (F18-FDG), injected intravenously. The CT scan was used for anatomical mapping and correcting for any interference (attenuation).
3. **Findings:**
 - **Neck/Thorax:** There's a lump (goiter) in the neck and a nodule in your right lung which has grown in size since the last scan and is showing increased FDG uptake. This means that the cells in the nodule are consuming more glucose than the surrounding cells, which can be a sign of cancerous activity. Despite this, no suspicious lymph nodes or potential spread of the cancer is identified in the neck, chest or armpit areas. Your heart appears enlarged, and there is hardening of the coronary and aortic arteries (sclerosis). You have had a mitral valve replacement in the past.
 - **Abdomen:** There are some low-density spots in the liver and kidneys, which might be cysts or benign tumors, but they are not showing any abnormal glucose metabolism. There are surgical clips present from previous surgery, likely a hernia repair. There are pockets or pouches (diverticulosis) present in your sigmoid colon, a part of the large intestine. No other abnormalities are detected in the abdomen.
 - **Musculoskeletal system:** No signs of abnormal bone metabolism that might indicate cancer spread. There is evidence of bone thinning (osteopenia) and arthritis (osteoarthritis and coxarthrosis) in both hips and particularly in the left shoulder. There is also a history of spinal fusion surgery in the lower back (lumbar region).
4. **Impression:** The primary finding of interest is the nodule in your right lower lung which has increased in size and is showing higher metabolic activity, indicative of a possible

non-small cell lung cancer (NSCLC). However, there are no signs that suggest the cancer has spread to the lymph nodes or elsewhere in the body.

Secondary findings include severe arthritis in the left shoulder and both hips, and a nodular goiter in the neck.

Remember, the interpretation of PET scans is complex and must be done in the context of your clinical history and other findings. You should discuss these results with your doctor for a comprehensive understanding and to plan for next steps in your care.

Trial #3

This is a report of a Positron Emission Tomography (PET) scan combined with Computed Tomography (CT). PET/CT scans are used to diagnose or monitor various health conditions, particularly cancer. The imaging allows doctors to see how organs and tissues inside your body are functioning on a cellular level, and the CT gives additional anatomical details.

The scan uses a radioactive drug (tracer) that's injected into your body, and this report used a tracer called F18-Fluorodeoxyglucose (F18-FDG), which is taken up by cells that use glucose for energy - such as cancer cells.

Here's a breakdown of the key points from your PET/CT report:

1. **Clinical question:** The report addresses whether a newly discovered nodule in your right lower lung might be cancerous, and if so, what stage it's at. It's also considering a secondary diagnosis of prostate cancer.
2. **Findings - Neck/Thorax:** The nodule in the right lower lobe of your lung has grown from 19mm to 22mm since your last CT scan. It also shows an increased uptake of the radioactive tracer (SUVmax of 7), indicating a high level of metabolic activity, which can be a sign of cancer. However, no other suspicious lymph nodes or metastases were found in this area.
3. **Abdomen:** There are some small hypodense lesions (areas that appear lighter on the scan) in your liver and both kidneys. These could be cysts, benign tumors, or other non-threatening conditions, but it's unclear from this report. There is also diverticulosis in your sigmoid colon (small pouches in your colon's lining), and surgical clips in your abdominal wall from a previous hernia surgery.
4. **Musculoskeletal system:** There's no evidence of cancer in your bones, but you do have osteopenia (lower than normal bone density), advanced left shoulder arthritis (omarthrosis), and hip arthritis (coxarthrosis) on both sides, with the left side more affected than the right. The report also mentions a previous spinal fusion surgery from the 2nd to 5th lumbar vertebrae and spondylolisthesis (slippage of a vertebra) at L4.
5. **Impression:** The main concern is the lung nodule, which has grown in size and shows metabolic activity typical of cancer. If it's a non-small cell lung cancer (NSCLC), it could be at stage T1c (where T stands for the size and extent of the main tumor), given there's no evidence of cancer spread to lymph nodes (N0) or distant parts of the body (M0).
6. **Secondary findings:** Other conditions found include advanced arthritis in your left shoulder and both hips, as well as a nodular goiter (an enlarged thyroid gland) causing a shift of your trachea (windpipe) to the right.

This report should be discussed in detail with your doctor, who can interpret the findings in the context of your overall health and medical history. If cancer is suspected, they may recommend further diagnostic procedures such as a biopsy.

R3Q1: How should my lung cancer be treated?

Trial #1

Lung cancer treatment depends on several factors, including:

1. The type of lung cancer (Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC))
2. The stage of the cancer (extent of spread)
3. Your overall health and fitness

According to the PET/CT report, it seems you likely have NSCLC, which is the most common type of lung cancer. As per the report, the cancer does not seem to have spread to the lymph nodes or distant sites, which would likely make it early-stage NSCLC (the report mentions T1c, N0, M0, which means a small primary tumor with no regional lymph node involvement and no distant metastasis). However, this will need to be confirmed by your treating physicians.

Treatment options for early-stage NSCLC may include:

Surgery: This is often the first-line treatment if the cancer is localized and you are fit for surgery. The type of surgery depends on the size and location of the tumor. Options include wedge resection (removing part of a lobe), segmentectomy (removing a larger portion but not the whole lobe), lobectomy (removing the entire lobe), or pneumonectomy (removing the entire lung).

Radiation Therapy: For patients who cannot have surgery due to other health issues, radiation therapy is another option. Stereotactic body radiotherapy (SBRT) is a specialized type of radiation therapy that delivers high doses of radiation to the tumor while minimizing radiation to the surrounding healthy tissues.

Radiofrequency Ablation (RFA): RFA may be used for small tumors in patients who can't undergo surgery or radiation.

Chemotherapy or targeted therapies: These treatments are usually reserved for more advanced stages or if the cancer returns after initial treatment. Some patients with certain genetic changes in their tumors may be candidates for targeted therapies, which specifically attack cancer cells with these changes.

Immunotherapy: This is a newer type of treatment that uses the body's immune system to fight cancer. It may be used in certain situations, usually for more advanced stages.

It's important to remember that the best treatment approach should be individualized to your specific condition and overall health status. Please discuss these options with your oncologist who can provide the best guidance based on your specific situation.

Also, your case might be discussed in a multidisciplinary team (MDT) meeting (also known as tumor board review), which involves various specialists such as a pulmonologist, a medical oncologist, a radiation oncologist, a pathologist, a radiologist, and a thoracic surgeon, to decide the most suitable treatment approach.

Remember that advances in medical science occur frequently, and there may be new treatments available or clinical trials that could be appropriate for you. Always discuss this with your oncology team.

Trial #2

The treatment of lung cancer depends on several factors including the type of lung cancer (small cell vs non-small cell), the stage of the disease, your overall health, and your personal preferences.

Based on your PET/CT report, if your lung nodule is confirmed as non-small cell lung cancer (NSCLC) and at stage T1c N0 M0, this suggests an early stage cancer (stage I), where the cancer is localized and hasn't spread to lymph nodes or distant parts of the body. The following treatments could be considered:

1. **Surgery:** This is often the first-line treatment for early stage NSCLC, and involves removing the tumor along with a margin of healthy tissue. The specific type of surgery depends on the tumor's location and size, and could include a wedge resection (removing a small section of the lung), segmentectomy (removing a larger portion), lobectomy (removing the entire lobe of the lung), or pneumonectomy (removing an entire lung).
2. **Stereotactic body radiotherapy (SBRT):** This is an option if surgery isn't suitable for you, for instance due to other medical conditions. SBRT involves delivering high doses of radiation precisely to the tumor, minimizing damage to surrounding healthy tissue.
3. **Adjuvant therapy:** After surgery, you may be offered chemotherapy, radiation therapy, or targeted therapy to kill any remaining cancer cells and reduce the risk of recurrence.
4. **Targeted therapy:** If your tumor has certain genetic mutations, targeted therapies can be used to specifically attack cancer cells with these mutations. This treatment is usually less harmful to normal cells compared to chemotherapy.
5. **Immunotherapy:** This is a relatively new type of treatment that helps your immune system fight cancer. It's typically used for advanced or recurrent NSCLC, but research is ongoing for its use in earlier stages.
6. **Watchful waiting or active surveillance:** If the tumor is very small and isn't causing any symptoms, your doctor might suggest watching it closely with regular scans, and initiating treatment only if it starts to grow or cause symptoms.

Your treatment should be individualized based on your specific circumstances, and should be discussed thoroughly with your healthcare provider, ideally in a multidisciplinary team meeting involving a thoracic surgeon, medical oncologist, radiation oncologist, pulmonologist, and other specialists as needed.

Remember, this advice is based on a hypothetical scenario given your PET/CT report, and actual treatment decisions should be based on a full clinical assessment and biopsy results confirming the diagnosis.

Trial #3

Treatment of lung cancer depends on a number of factors including the type of lung cancer (non-small cell lung cancer or small cell lung cancer), the stage of the cancer, the genetic makeup of the cancer, the patient's overall health, and the patient's preferences.

Here's an overview of potential treatment options:

1. **Surgery:** This is often an option for early-stage non-small cell lung cancer. The surgeon may remove a portion of the lung, a whole lobe, or the entire lung depending on the size and location of the tumor. Lymph nodes in the chest may also be removed to check for cancer cells.
2. **Radiation therapy:** This uses high-powered energy beams to kill cancer cells. It can be used as the primary treatment for people who aren't good candidates for surgery, such as those with poorer health or advanced lung cancer. It can also be used after surgery to kill any remaining cells, or to relieve symptoms of advanced cancer.
3. **Chemotherapy:** This uses drugs to kill cancer cells throughout the body. It can be given after surgery to kill any remaining cancer cells, combined with radiation therapy if surgery isn't an option, or used to relieve symptoms of advanced cancer.
4. **Targeted therapy:** Some lung cancers have specific genetic mutations that allow them to grow. Targeted therapies are drugs that have been developed to target these mutations, inhibiting the cancer's ability to grow and spread. They are usually used in advanced or recurrent non-small cell lung cancer.
5. **Immunotherapy:** This is a newer category of drugs that work by helping the body's immune system to fight cancer. They can be used when lung cancer is advanced, especially if it has certain characteristics.
6. **Palliative care:** This is care given to improve the quality of life for patients who have a serious or life-threatening disease, like lung cancer. It can be used to alleviate symptoms and side-effects from cancer and its treatment.

It's very important to discuss these options and their potential side effects with your healthcare team. They can recommend a treatment plan tailored specifically to your situation. Also, clinical trials might be an option for you. These can give you access to treatments that are still under investigation and not yet available in general practice.

Keep in mind this is a general overview of possible treatments for lung cancer. Your specific treatment may be different based on your individual condition and medical history. Treatment decisions should always be made in consultation with your healthcare provider.

Can you give me the references?

Absolutely, here are some references where you can find more information about the topics discussed:

1. American Cancer Society. (2021). Non-Small Cell Lung Cancer Stages. [Link](#)
2. American Cancer Society. (2021). Surgery for Non-Small Cell Lung Cancer. [Link](#)
3. Mayo Clinic. (2021). Lung Cancer. [Link](#)

4. National Cancer Institute. (2021). Non-Small Cell Lung Cancer Treatment (PDQ®)–Patient Version. [Link](#)
5. American Cancer Society. (2021). Radiation Therapy for Non-Small Cell Lung Cancer. [Link](#)
6. Cancer Research UK. (2021). Radiofrequency Ablation for Lung Cancer. [Link](#)
7. National Cancer Institute. (2021). Lung Cancer Treatment (PDQ®)–Health Professional Version. [Link](#)
8. American Cancer Society. (2021). Targeted Therapies for Non-Small Cell Lung Cancer. [Link](#)
9. American Cancer Society. (2021). Immunotherapy for Non-Small Cell Lung Cancer. [Link](#)

Please note that all the information provided by these links is accurate as of my knowledge cutoff in September 2021, and there may have been advancements or changes in the field since then. Always consult with your healthcare provider for the most current information.

R4: Please explain my PET report to me:

Whole-body PET/CT with F18-FDG from 05/02/2021:

Clinical question, justifying indication:

Patient with initial diagnosis of NSCLC/ADC. Staging before initiation of therapy.

Procedure: Topogram for examination planning followed by a low-dose CT (skull base to upper third of femur) for attenuation correction and for anatomical mapping. PET emission measurement was performed after intravenous injection of 241 MBq of F18-FDG without complications (uptake phase: 57 minutes, blood glucose: 107 mg/dl).

Additionally, MSCT from skull base to upper third of femur (venous phase) after application of 100 ml of Imeron 350 without complications. Thin layer and 2D reconstructions. Total DLP: 1197 mGy*cm.

Findings:

Multiple prior images, including a CT from 04/04/2021, were available for comparison.

Neck:

There is normal pneumatization of the paranasal sinuses and mastoid cells.

There is focal hypermetabolism on the left side along the soft palate at the junction to the left tonsil (SUVmax of approx. 8), correlating with a faintly contrast enhancing, asymmetrical soft tissue lesion (Series 5, slice 26). Progressive nodular goiter compared to 12/2017, predominantly on the left side, with a mainly cystic nodule extending far into the mediastinum but without relevant tracer uptake (37 x 52 mm, previous CT: 29 x 45 mm, SUVmax of 2.8). Otherwise, there is normal FDG uptake in the neck with symmetric soft tissues. There is no cervical lymphadenopathy.

Thorax:

There is a spiculated solid pulmonary nodule with constant size in the short term located in the posterior right upper lobe with intense FDG uptake (Series 8, slice 148, 24 x 27 mm, SUVmax approx. 19). There are no further pulmonary nodules or FDG-positive pulmonary lesions. Status post sublobar resection of the left lower lobe. There is pulmonary emphysema and bullae, especially at the base of the left lung. There are no pneumonic infiltrates. There is no pleural effusion and no pneumothorax. As a result of the thyroid nodule, the trachea is shifted to the right.

A prominent hilar lymph node on the right with a short axis diameter of 10 mm (IASLC 10R) and an infracarinal mediastinal lymph node measuring 7 mm (IASLC 7) are noted, both with intense FDG uptake (Series 5, slice 170 and 180, SUVmax of approx. 5 and 7, respectively). In addition, there are three prominent right para-/retrotracheal lymph nodes (IASLC 3P) with faint tracer uptake (short axis up to 10 mm, SUVmax up to approx. 2.5). There is no left hilar or axillary lymphadenopathy.

The heart is of normal size. There is a constant pericardial effusion measuring approximately 14 mm. There is calcification of the coronary arteries and thoracic aorta. Hiatal hernia.

Abdomen:

There is steatosis hepatis. Fatty atrophy of the pancreas. Both adrenal glands are normal. There are hypotrophic kidneys with cortical and parapelvic cysts. Nephrolithiasis is noted on the right.

Otherwise, the abdominal organs, pelvic organs, and intestine are normal on PET and CT. There is no free fluid or free air. The pelvic, retroperitoneal, and mesenteric lymph nodes appear normal on PET and CT. There is a ventriculoperitoneal shunt ending at the right renal fascia without abnormal tracer uptake. There is a fat-filled umbilical hernia without signs of incarceration. Calcification of the abdominal aorta and iliac vessels is noted.

Musculoskeletal system:

There is diffuse tracer uptake in L1, which is slightly reduced in height compared to the last CT from 12/5/2014 (previous CT: 27 mm in height, currently 24 mm). There is a minor, subacute impaction with reparative processes emphasized at the intact base plate of L1, with vacuum phenomenon of the adjacent disc. Furthermore, degenerative changes of the vertebral column are noted, especially of the thoracolumbar segments. There are no suspicious blastic or lytic lesions on CT and no suspicious hypermetabolic bone lesions on PET.

Impression:

- At first diagnosis of an NSCLC/ADC, the known primary tumor on the posterior right upper lobe measures 27 mm, is spiculated and hypermetabolic.
- There are hypermetabolic hilar and mediastinal lymph node metastases in IASLC levels 10R and 7 and suspicious lymph nodes in IASLC level 3R.
- There is no evidence of hypermetabolic organ or bone metastases.

Secondary findings

- There is unclear focal hypermetabolism on the left side of the soft palate (cranial to the palatal tonsil) with contrast enhancement. Clinical correlation is recommended.
- Suspected subacute impaction of L1 with reparative FDG uptake.
- Progressive left multinodular goiter extending to the mediastinum. If not already done, consultation of an endocrinologist is recommended.

Trial #1

Your PET/CT scan report covers your whole body with special attention to different regions like the neck, thorax, abdomen, and musculoskeletal system. PET/CT scans are typically performed to check the progress of diseases like cancer and evaluate how effective treatments are. The FDG (fluorodeoxyglucose) you were given before the scan is a type of radioactive sugar that cancer cells absorb more readily than healthy cells, thus highlighting potential problem areas. The SUVmax mentioned in your report stands for maximum Standard Uptake Value, a measure of how much of this radioactive sugar is being absorbed in certain areas, with higher values typically indicating greater concern.

Here's a summary of what the report says:

Neck:

The report shows normal airspaces in the paranasal sinuses and mastoid cells, which are areas in your head. However, there's an area of increased metabolic activity (higher FDG uptake) on the left side of your soft palate at the junction to the left tonsil, which correlates with an asymmetrically enhancing soft tissue lesion. This might be a cause for concern and further investigation might be needed. There's also an increase in the size of a mainly cystic thyroid nodule, extending into the mediastinum, compared to the previous examination, but without a significant tracer uptake. This could be indicative of a goiter, which is an enlargement of the thyroid gland.

Thorax:

There's a spiculated (spiky or pointy in shape, which can suggest a malignancy) solid pulmonary nodule in the posterior right upper lobe of your lung. The nodule shows intense FDG uptake, suggesting that it might be cancerous. This is consistent with your initial diagnosis of Non-Small Cell Lung Cancer/Adenocarcinoma (NSCLC/ADC). Additionally, several lymph nodes in the region of your right lung (IASLC levels 10R, 7, and 3P) show varying degrees of tracer uptake, which could suggest the cancer has spread to these lymph nodes.

Abdomen:

The report mentions steatosis hepatis (fatty liver disease), fatty atrophy of the pancreas, hypotrophic kidneys with cortical and parapelvic cysts, and nephrolithiasis on the right (kidney stones). No abnormalities were detected in the abdominal organs, pelvic organs, and intestines.

Musculoskeletal system:

The report notes some changes in your L1 vertebrae, suggesting a slight decrease in its height and signs of subacute impaction. There is also some degeneration of the vertebral column, particularly in the thoracolumbar segments. However, no suspicious bone lesions were found on the PET scan, meaning there doesn't appear to be any metastatic spread of the cancer to the bones.

Impression:

This summarizes the primary findings. It notes the known lung tumor in the right upper lobe, as well as the lymph node metastases. Importantly, it also states that there doesn't appear to be any metastatic spread of the cancer to other organs or the bones.

Secondary findings:

In addition to the primary findings, there's an area of concern on the left side of your soft palate that needs further evaluation. Also, the report suggests consulting an endocrinologist about your progressive goiter (thyroid enlargement).

Please discuss this report further with your doctor, who will be able to provide a comprehensive interpretation based on your complete medical history and condition. They will advise you on the next steps and possible treatments if necessary.

Trial #2

Your PET (Positron Emission Tomography) report contains a lot of information, but I'll do my best to explain the key points:

1. **Clinical question and Procedure:** The PET scan was done to stage your Non-Small Cell Lung Cancer/Adenocarcinoma (NSCLC/ADC) before initiating therapy. F18-FDG (fluorodeoxyglucose), a type of radioactive glucose, was injected into your body to highlight areas of abnormal metabolism, often associated with cancer cells. CT scans were also performed for better localization and anatomy.
2. **Neck:** An area of increased FDG uptake on the left side of the soft palate next to the left tonsil was found. This indicates higher metabolic activity and could represent a malignancy or infection. Your thyroid gland has grown since last checked, particularly a cystic nodule on the left side extending into the mediastinum, but it doesn't appear to have a significant FDG uptake which might suggest it's not cancerous. There are no enlarged lymph nodes in the neck, which is good as it means no obvious spread of cancer in this area.
3. **Thorax (Chest):** The primary tumor in your right upper lung has not grown in size, which is good news. The intense FDG uptake suggests that this is likely the main cancerous area. Some lymph nodes in your chest are enlarged and show high FDG uptake, suggesting they might be involved with cancer. The left side of your chest shows signs of emphysema and bullae, which are related to lung damage, not the cancer. There's also a pericardial effusion (fluid around the heart), which could be due to a variety of conditions and should be monitored.
4. **Abdomen:** There are a few abnormalities here, such as fatty liver and fatty atrophy of the pancreas, as well as some kidney cysts and stones, but none of these show signs of cancer. There is no abnormal FDG uptake suggesting metastasis (spread of cancer) in this region.
5. **Musculoskeletal system:** There are degenerative changes in your vertebral column and specifically in the L1 vertebra, but there are no signs of cancer spread to the bones.
6. **Impression:** The cancer (NSCLC/ADC) appears to be localized to the right upper lobe of the lung, with possible spread to nearby lymph nodes. There are no signs of spread to other organs or bones.
7. **Secondary findings:** There is an area of high metabolic activity on the left side of the soft palate, which may need further investigation. The changes in the L1 vertebra are likely due to non-cancerous causes, such as injury or degeneration. Your thyroid gland is enlarged, which might need evaluation by an endocrinologist.

This is a general interpretation of your PET scan, and you should discuss the findings with your doctor for a full understanding and to decide the next steps in your treatment.

Trial #3

I'm an AI and not a doctor, but I can certainly help explain the medical terminology and general findings of this PET/CT report.

The PET/CT scan was conducted for staging purposes after you were diagnosed with Non-Small Cell Lung Cancer (NSCLC) of the adenocarcinoma (ADC) subtype. This is done before starting therapy to understand the extent of the disease.

Here are the findings:

1. **Neck:** The scan shows an area of increased metabolic activity in the soft palate at the junction to the left tonsil. This could indicate disease, but other non-cancerous conditions

can also cause this. The scan also shows an increase in the size of your thyroid gland, with a cystic nodule that extends into your chest (mediastinum). This doesn't seem to be related to cancer as it doesn't show significant uptake of the tracer used in the PET scan.

2. **Thorax:** A solid pulmonary nodule (small, abnormal growth) is seen in the posterior right upper lobe of your lung, which shows high FDG uptake. This is likely the primary lung tumor. Additionally, several lymph nodes in the chest area (hilar and mediastinal) show increased FDG uptake, suggesting possible spread of cancer to these nodes. Your heart appears normal in size, although there is some pericardial effusion (fluid around the heart). This could be related to the cancer or other heart conditions.
3. **Abdomen:** The report mentions fatty liver (steatosis hepatis), fatty atrophy of the pancreas, hypotrophic kidneys (smaller than normal), and some kidney stones. These findings are not directly related to lung cancer but might be important for your overall health management. There is no evidence of cancer spread to the abdomen.
4. **Musculoskeletal system:** There's a note about changes in your lumbar spine (L1), with increased tracer uptake, which might indicate an injury or disease. However, there's no evidence of cancer spread to the bones.

In summary, the report concludes that the primary tumor is located in your lung (27mm, spiculated, and hypermetabolic). There are possible metastases (cancer spread) to lymph nodes in the chest, but there is no evidence of cancer spread to organs or bones elsewhere in the body.

Additionally, there are some secondary findings. A suspicious area of increased metabolic activity at the left side of the soft palate needs further investigation, and the increasing size of the goiter (enlarged thyroid gland) suggests a consultation with an endocrinologist, a specialist in hormone-related conditions.

It's important to discuss these findings with your doctor, who can interpret them in the context of your overall health and clinical picture. They can also advise on the best course of treatment.

R4Q1: What's my cancer stage?

Trial #1

Staging for lung cancer typically uses the TNM system, which classifies tumors based on the size and extent of the primary Tumor (T), whether cancer cells have spread to nearby lymph Nodes (N), and the presence of distant Metastasis (M). Unfortunately, the PET report provided does not contain enough detailed information to assign an exact stage to your lung cancer.

However, the report does indicate that your cancer appears to have spread to nearby lymph nodes (as mentioned in the thorax section), suggesting it is at least stage II, and could be stage III if the cancer has spread to more distant lymph nodes in the chest. The fact that there are no signs of distant metastasis (cancer spread to other organs) is good news and suggests your cancer may not be stage IV.

Your physician, possibly with the help of a pathologist, would be the most appropriate person to determine your exact stage using this information, as well as any other test results or imaging you've had. Please consult them for an accurate diagnosis.

Trial #2

Based on the provided PET/CT report, it appears that you have Non-Small Cell Lung Cancer (NSCLC), adenocarcinoma subtype, which appears to have spread to regional lymph nodes but not to distant organs or bones.

According to the TNM staging system (Tumor, Node, Metastasis) often used for lung cancer:

- Tumor (T): The primary tumor in your right upper lung lobe measures 27mm. This would likely put it at T1b or T2a, as T1b involves tumors >1cm but ≤3cm and T2a involves tumors >3cm but ≤4cm. However, this depends on other factors like its location in relation to the bronchus, so the final T stage would be determined by your healthcare team.
- Node (N): There are hilar and mediastinal lymph nodes that are showing intense FDG uptake, suggesting they have cancer cells. Depending on the exact location and number of lymph nodes involved, this could fall into N1, N2 or N3.
- Metastasis (M): No distant metastasis (M0) is mentioned in the report, meaning the cancer does not appear to have spread to other organs or bones.

Given these findings, your cancer might be at a clinical stage of II or III. However, it's crucial to note that the exact stage can only be determined by your healthcare provider, who will consider these results alongside other diagnostic tests and clinical evaluations. Please consult with your healthcare provider for a more accurate staging and treatment plan.

Trial #3

The staging of your cancer depends on the tumor size, its location, whether it has spread to nearby lymph nodes, and whether it has spread (metastasized) to distant sites in the body.

Based on the provided PET/CT report, it seems like the primary tumor in the right upper lobe of your lung is about 27mm. Also, there are suspected lymph node metastases, with high FDG uptake in lymph nodes in the chest (IASLC levels 10R, 7 and 3P).

The staging of NSCLC (Non-Small Cell Lung Cancer) follows the TNM system - Tumor, Nodes, and Metastasis:

1. T describes the size of the primary tumor and whether it has invaded nearby structures.
2. N describes nearby (regional) lymph nodes that are involved.
3. M describes distant metastasis.

According to this system, you would likely be classified as:

- T: T1c (for a tumor size of 27mm).
- N: At least N2 (involvement of mediastinal lymph nodes, as suggested by high FDG uptake).

- M: M0 (since there is no mention in the report of distant metastasis).

This would place you at stage IIIA or IIIB. However, I need to stress that this is a rough estimation based on the limited information in your report. It's crucial that you discuss this with your oncologist or healthcare provider, who can give you a definitive stage based on a more comprehensive evaluation of your condition. The exact stage can significantly impact the treatment options and prognosis.

R4Q2: How should my lung cancer be treated?

Trial #1

The treatment for non-small cell lung cancer (NSCLC), such as adenocarcinoma (ADC), depends on a variety of factors including the stage of the disease, the patient's overall health and lung function, and the patient's personal preferences. As of my knowledge cutoff in 2021, common treatment options include:

1. **Surgery:** This is often the preferred treatment for early-stage NSCLC (stages I and II, and some stage IIIA cancers), where the tumor is localized and can be completely removed. Types of surgery include wedge resection (removal of a small part of the lung), segmentectomy (removal of a larger part of the lung), lobectomy (removal of an entire lobe of the lung), and pneumonectomy (removal of an entire lung).
2. **Radiotherapy:** Radiation therapy uses high-energy beams to destroy cancer cells. This may be used after surgery to kill any remaining cancer cells, or as the main treatment in cases where surgery is not an option. Stereotactic body radiotherapy (SBRT) is often used for early-stage lung cancers when surgery is not an option due to a person's health.
3. **Chemotherapy:** This is a systemic therapy, meaning it affects the entire body. Chemotherapy might be used before surgery to shrink a tumor, after surgery to kill remaining cells, or as the main treatment for cancers that have spread or in persons who are not surgical candidates. It's often combined with radiation therapy in the treatment of stage III lung cancer.
4. **Targeted Therapy:** These drugs target specific mutations or abnormalities in the cancer cells. Not all lung cancers will have these mutations, but if they do, drugs targeting EGFR, ALK, ROS1, BRAF, MET, RET, and other genetic changes might be used. They're typically used in advanced-stage disease or when cancer has come back after initial treatment.
5. **Immunotherapy:** This is a relatively newer type of cancer treatment that helps your immune system fight cancer. These drugs are often used in the treatment of advanced or metastatic NSCLC, and in some cases might be used as a first-line therapy.
6. **Palliative Care:** This form of care is used to alleviate symptoms and improve quality of life, but not to cure the disease. It's often used in conjunction with other treatments.

Since your PET/CT scan suggests that the cancer has spread to nearby lymph nodes but not to distant organs or bones, your treatment might involve a combination of therapies. Please note that this is a very general overview and treatment regimens can change as new therapies are developed and as more is learned about the specific subtype of lung cancer you have.

Your oncologist is the best person to discuss treatment options with, as they will be able to provide personalized recommendations based on your specific case and overall health status. Additionally, they may consider genetic testing of your tumor to identify any specific mutations which could guide treatment decisions.

Trial #2

The treatment of non-small cell lung cancer (NSCLC) depends on multiple factors, including:

- The stage of the disease
- The type and genetic characteristics of the tumor
- Your overall health status and preferences

Based on the information you've provided, which suggests your cancer may be stage IIIA or IIIB, the following treatments may be considered:

1. **Surgery:** Surgery may be an option if the tumor is localized and can be completely removed. In stage III lung cancer, surgery might be used after chemotherapy or chemoradiation (neoadjuvant therapy) or may be followed by chemotherapy or chemoradiation (adjuvant therapy). The type of surgery depends on the tumor's location and size. Options may include wedge resection (removing a small part of the lung), lobectomy (removing the entire lobe of the lung), or pneumonectomy (removing an entire lung).
2. **Radiation Therapy:** Radiation therapy uses high-energy rays to kill cancer cells. It may be used before surgery (neoadjuvant therapy), after surgery (adjuvant therapy), or as the main treatment if surgery isn't an option. Sometimes, radiation therapy is combined with chemotherapy, a combination known as chemoradiation.
3. **Chemotherapy:** Chemotherapy uses drugs to kill cancer cells throughout the body. It can be used before surgery (neoadjuvant), after surgery (adjuvant), or as the main treatment if surgery isn't possible. Chemotherapy is often combined with radiation therapy for stage III NSCLC.
4. **Immunotherapy:** Immunotherapy drugs stimulate the body's immune system to fight cancer cells. They may be used alone or in combination with chemotherapy for advanced-stage NSCLC.
5. **Targeted Therapy:** If the cancer cells have certain genetic mutations, targeted drugs can be used to attack specific types of cancer cells.

The decision of which treatment to use and in what order depends on many factors, including the exact stage and genetic characteristics of your cancer, your overall health status, and your personal preferences. Some people might receive more than one type of treatment, and others might receive only one type. It's important to have detailed discussions with your healthcare team to understand the potential benefits and risks of each treatment option for your specific case.

Trial #3

The treatment of non-small cell lung cancer (NSCLC) depends on multiple factors, including the type of cancer, the stage of the disease, the patient's overall health, and the patient's

preferences. As of my knowledge cutoff in September 2021, here are some possible treatment strategies:

1. **Surgery:** If the cancer is localized and hasn't spread beyond the lungs (typically stage I or II), surgery to remove the tumor can be an option. The specific type of surgery depends on the tumor's size and location and can include a wedge resection (removal of a small section of the lung), segmentectomy (removal of a larger portion of the lung), lobectomy (removal of an entire lobe of the lung), or pneumonectomy (removal of an entire lung). However, in your case, given the likely involvement of mediastinal lymph nodes (stage III), surgery alone may not be sufficient.
2. **Radiation Therapy:** This can be used as the primary treatment in patients who are not surgical candidates or in combination with chemotherapy for patients with locally advanced disease (like stage III). Radiation therapy can also be used to relieve symptoms in patients with advanced NSCLC.
3. **Chemotherapy:** This is typically used before surgery to shrink tumors (neoadjuvant therapy), after surgery to kill any remaining cancer cells (adjuvant therapy), or as the primary treatment for cancers that have spread beyond the lung or in people who aren't healthy enough for surgery.
4. **Immunotherapy:** Immunotherapy drugs stimulate the body's immune system to fight cancer cells. They have been increasingly used for advanced NSCLC, sometimes in combination with chemotherapy.
5. **Targeted Drug Therapy:** These treatments target specific abnormalities present within cancer cells. To consider this treatment, your doctor may order a biopsy to test for certain gene mutations in the cancer cells, such as EGFR, ALK, ROS1, or others. If such mutations are present, there are specific drugs that can target these changes.
6. **Palliative Care:** This is supportive care to help patients manage symptoms and side effects. It's often used in conjunction with other treatments for patients at any stage of disease.

Please consult with your oncologist or a healthcare professional to discuss the best treatment options for your specific condition. Also, treatments may have advanced beyond my training data, which is up-to-date until September 2021, and newer therapies might be available now.

Can you give me the references?

Certainly, here are some references based on my training data up to September 2021 that could be useful for you:

1. American Cancer Society. (2021). Treatment Choices for Non-Small Cell Lung Cancer, by Stage. [Online] Available at: <https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/by-stage.html>
2. National Cancer Institute. (2021). Non-Small Cell Lung Cancer Treatment (PDQ®)—Patient Version. [Online] Available at: <https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq>
3. Mayo Clinic. (2021). Non-small cell lung cancer. [Online] Available at: <https://www.mayoclinic.org/diseases-conditions/non-small-cell-lung-cancer/diagnosis-treatment/drc-20352474>

4. National Comprehensive Cancer Network. (2021). NCCN Guidelines for Patients: Non-Small Cell Lung Cancer. [Online] Available at: <https://www.nccn.org/patients/guidelines/content/PDF/lung-nsclc-patient.pdf>
5. Lung Cancer Foundation of America. (2021). Stages of Lung Cancer. [Online] Available at: <https://lcfamerica.org/lung-cancer-info/stages-of-lung-cancer/>

Please note that this information was up to date as of my last training data in September 2021, and there may be more current information or treatments available. Always consult with your healthcare provider for the most accurate and up-to-date information.

R5: Please explain my PET report to me:

Whole-body PET/CT with F18-FDG from 08/20/2021:

Clinical question, justifying indication: patient with suspected metastatic lung cancer. Staging.

Procedure: Topogram for examination planning followed by a low-dose CT (skull base to upper third of femur) for attenuation correction and for anatomical mapping. PET emission measurement was performed after intravenous injection of 237 MBq of F18-FDG without complications (uptake phase: 65 minutes, blood glucose: 122 mg/dl).

Additionally, MSCT from skull base to upper third of femur (venous phase) after application of 90 ml of Imeron 350 without complications. Thin layer and 2D reconstructions. Total DLP: 755 mGy*cm.

Findings:

Multiple prior images, including a CT from 08/11/2021, were available for comparison.

Neck:

There is normal pneumatization of the paranasal sinuses and mastoid cells. The thyroid gland is significantly enlarged and displaces the trachea to the left with an extensive nodule in the right thyroid lobe that reaches to the mediastinum and shows focally increased FDG uptake in its cranial part (SUVmax of 6.1). In addition, faint FDG uptake is seen in the left thyroid lobe (SUVmax 3.1). Otherwise, there is normal FDG uptake in the cervical region with symmetric soft tissues.

Multiple enlarged infraclavicular and cervical lymph nodes in level IV are noted, either without or with only faint FDG uptake (e.g., Series 16, Image 125; 17 mm in short axis diameter; SUVmax 1.8). There is no cervical lymphadenopathy on the left.

Thorax:

There is an atelectasis of the right upper lobe with inhomogeneous internal structure, in parts hypodense with marginal contrast enhancement (cf. Series 16 Image 171) as well as strong FDG uptake in the center (SUVmax of approx. 8). There is a diffuse soft tissue mass extending from the atelectasis to the mediastinal lymph nodes in IASLC level 4R, not reliably distinguishable from the hilar/mediastinal lymph nodes, with broad contact to the superior vena cava (infiltration?) and intensive FDG uptake (SUVmax approx. 7). There are multiple adjacent mediastinal lymph nodes (level 2R, 4R+L, 7, and ventral to the ascending aorta), some enlarged and with necrotic center, each with increased tracer uptake, e.g., in IASLC level 2R (Series 14 Image 159; short axis diameter of 21 mm, SUVmax approx. 7). There is no lymphadenopathy in the left hilus or axilla.

There are multiple additional solid pulmonary nodules in both lungs, some located adjacent to the pleura, most of them hypermetabolic (e.g., Series 15 Im 59, max 13 mm, SUVmax approx. 4). There are no pneumonic infiltrates. A narrow pleural effusion is noted on both sides (maximum width of 7 mm). There is no pneumothorax. The heart is of normal size, and there is no pericardial effusion. Discrete calcification of the mitral valve, aortic valve, and thoracic aorta.

Abdomen:

There are hypodense, lesions with ill-defined borders in both lobes of the liver, in segments VII/VIII some of them confluent and each with intense hypermetabolism, e.g. in segment III (Series 14 Image 301; maximum diameter of 30 mm, SUVmax of 12). Focal, partially calcified adenomyomatosis is noted at the gallbladder fundus. Cholecystolithiasis. The pancreas is hypotrophic. The left adrenal gland is markedly enlarged showing a nodular lesion and increased FDG uptake (SUVmax of approx. 12). In addition, there is a moderately hypermetabolic nodule of 8 mm in the medial limb of the right adrenal gland (Series 16 Image 316, SUVmax of 3.8). Cortical renal cysts are noted on both sides. The prostate gland is enlarged (31 x 44 mm) with inhomogeneous internal structure, macrocalcifications, and diffuse and faint tracer uptake, especially in the apical peripheral zone (SUVmax of 5.1). There is tracer accumulation in the ascending colon (SUVmax of 6.5) without definite correlate on CT, most likely from chronic inflammation. There is diverticulosis of the sigmoid colon.

Otherwise, the abdominal organs, pelvic organs, and intestine are normal on PET and CT. There is no free fluid or free air. The pelvic, retroperitoneal, and mesenteric lymph nodes appear normal on PET and CT. Calcification of the abdominal aorta and iliac vessels is noted. There is total occlusion of the entire right iliac artery.

Musculoskeletal system:

In status post laminectomy of L2 and dorsal stabilization of T12 to L4, there is moderate FDG uptake of the fractured vertebral body of L2 (SUVmax approx. 4). There is a lytic lesion in the 5th rib on the left. There are rib fractures on the right (rib 2 to 9) with associated, most likely posttraumatic FDG uptake (SUVmax approx. 3). An encapsulated fluid retention is noted in the right hip without increased FDG uptake.

Impression:

- There is a poorly defined, hypermetabolic pulmonary mass of approx. 50 mm in the central right upper lobe, typical of lung cancer, with poststenotic atelectasis due to tumor-related bronchial obstruction.
- The atelectasis in the right upper lobe shows signs of an empyema.
- There are multiple additional hypermetabolic pulmonary nodules in all remaining lobes of both lungs, most likely pulmonary metastases.
- There are hypermetabolic mediastinal lymph node metastases (IASLC 2R, 4R+L, 7, 3A) and infraclavicular lymph node metastases on the right.
- There are disseminated, hypermetabolic liver metastases.
- Hypermetabolic adrenal metastasis on both sides.
- Lytic bone metastasis in the left 5th rib.

Secondary findings:

- Occlusion of the entire right external iliac artery.
- Extensive nodular goiter with focal hypermetabolism in the upper right lobe. Endocrinological work-up is recommended.
- Fractures of the 2nd to 9th rib on the right.

Trial #1

Your PET/CT report is quite complex, with several key findings related to the lung cancer you've been diagnosed with as well as additional, secondary findings. Let's break it down:

Primary Findings:

1. **Lung Cancer:** The report indicates a large, hypermetabolic mass in your right upper lung. This mass is likely the primary cancer. It is obstructing the bronchial airways leading to atelectasis (collapse of part of the lung). The report also mentions signs of empyema, which is an infection in the lung that can happen when the lung collapses and is a serious complication.
2. **Pulmonary Nodules:** There are multiple additional small masses in the lungs, likely representing metastases, meaning that the lung cancer has spread to other parts of the lungs.
3. **Mediastinal and Infraclavicular Lymph Node Metastases:** These are lymph nodes located in the central part of the chest and below the collar bone, respectively, that are also showing increased metabolic activity suggesting that they are affected by cancer.
4. **Liver Metastases:** There are lesions in the liver that are also hypermetabolic, indicating that the lung cancer has spread to the liver.
5. **Adrenal Metastases:** The adrenal glands, which sit above your kidneys, show signs of cancer spread as well.
6. **Bone Metastasis:** A lytic lesion is present in the 5th rib on your left side. This lesion, which is a spot where the bone is being destroyed, is another sign of metastasis.

Secondary Findings:

- **Right External Iliac Artery Occlusion:** This means that the main artery supplying blood to your right leg is blocked. This condition could potentially cause pain or trouble walking if it's not treated.
- **Nodular Goiter:** Your thyroid gland, located in your neck, is significantly enlarged. This is called a goiter. There's also increased metabolic activity in part of the gland, suggesting a need for further endocrinological work-up to rule out thyroid disease.
- **Fractures:** Fractures of several ribs on your right side are noted. These are associated with some uptake of the tracer, which might suggest that these fractures are relatively recent or are causing inflammation.

The report is indicating that your lung cancer is at an advanced stage with spread to multiple body parts (metastasis). This requires a multi-disciplinary approach to treatment, likely including oncologists, radiologists, and potentially surgeons or interventional radiologists. Treatment options might include chemotherapy, targeted therapy, immunotherapy, or palliative care to manage symptoms. I recommend discussing the findings and potential next steps in detail with your healthcare provider.

Trial #2

Your PET/CT report indicates multiple findings that are suggestive of widespread cancer, presumably originating from the lungs.

1. **Neck:** The thyroid gland is enlarged with a large nodule that is active on PET scan, indicating it's metabolically active which could be suspicious for malignancy. Enlarged lymph nodes were also identified, but they are only faintly active, which could be due to either benign or malignant conditions.
2. **Thorax (Chest):** There is a collapsed lung (atelectasis) in the right upper lobe with an abnormal growth (likely a cancerous tumor) within it. This growth extends towards the middle of the chest, where it is difficult to separate it from the surrounding lymph nodes. These lymph nodes also show increased metabolic activity, suggesting they could be involved with cancer as well. There are additional lung nodules which may represent additional sites of cancer spread within the lungs (metastases). There are small amounts of fluid in the lining of both lungs (pleural effusions), which can be caused by various conditions including cancer.
3. **Abdomen:** There are abnormal, metabolically active lesions in both lobes of the liver and in the adrenal glands which are likely to represent metastatic cancer spread. There are also other non-cancer-related findings in this area, like cholecystolithiasis (gallstones), calcified gallbladder, pancreatic shrinkage, enlarged prostate, and diverticulosis of the sigmoid colon. Of note, the entire right iliac artery (a major artery in the pelvis) is blocked (occluded).
4. **Musculoskeletal system:** There are signs of past spine surgery (laminectomy and stabilization), as well as a metabolically active fracture in the second lumbar vertebra (L2). A lytic (destruction of bone) lesion in the left 5th rib is noted, which is likely another site of cancer spread (metastasis). There are also fractures of multiple ribs on the right, which have mild metabolic activity likely related to healing process.

The overall impression of this report is that there is widespread cancer that appears to have originated in the right upper lobe of the lung and spread (metastasized) to the lymph nodes, other parts of the lung, liver, adrenal glands, and bones. This condition is serious and will likely need aggressive management and treatment.

The report also notes an extensive nodular goiter (enlarged thyroid) with an active part in the right lobe that should be evaluated further. Additionally, the report mentions the occlusion of the entire right external iliac artery which is an important finding and would require further assessment and management.

Please note, these findings should be discussed in detail with your treating physician who can explain these findings better in the context of your entire medical history and recommend an appropriate treatment plan.

Trial #3

This PET/CT scan report suggests that you have been under investigation for suspected metastatic lung cancer. The report has detailed findings from a PET/CT scan. The PET (Positron Emission Tomography) part of the scan uses a radioactive sugar (F18-FDG) that cancer cells take up more than normal cells, which can then be detected on the scan. The CT (Computed Tomography) part provides detailed images of the body.

Here are the key findings:

1. **Lung cancer:** There is a poorly defined, hypermetabolic mass in the central right upper lobe of the lungs, likely indicative of a primary lung cancer. It seems to be causing atelectasis (collapse) of that part of the lung due to bronchial obstruction by the tumor.
2. **Pulmonary metastases:** The report describes additional smaller nodules in both lungs. These are hypermetabolic (taking up a lot of the radioactive sugar), suggesting they are likely cancerous and could represent metastases (spread of the cancer) from the primary lung tumor.
3. **Lymph node involvement:** Lymph nodes in several locations, including the mediastinal and infraclavicular regions, show increased metabolic activity, suggesting they may contain metastatic cancer cells.
4. **Liver metastases:** There are several hypermetabolic lesions in the liver, suggesting the presence of liver metastases.
5. **Adrenal gland metastases:** The adrenal glands (small glands above the kidneys) also show hypermetabolic lesions, which could indicate metastatic spread to these sites as well.
6. **Bone metastasis:** A lytic (destructive) lesion was found in the 5th rib on the left, likely indicating a bone metastasis.

Secondary findings:

1. **Vascular:** There's occlusion (blockage) of the entire right external iliac artery, a significant artery supplying blood to the leg. This may need further evaluation and management.
2. **Thyroid:** Your thyroid gland is significantly enlarged, with nodules that show increased uptake of the radioactive sugar. This could indicate a thyroid disease or potentially a thyroid cancer and warrants further investigation.
3. **Bone:** The report notes fractures in multiple ribs on the right side.

Overall, this report suggests a diagnosis of lung cancer that has spread (metastasized) to multiple other areas of the body, including the lymph nodes, liver, adrenal glands, and bones.

This is a serious condition and will likely require aggressive treatment. It's essential to discuss these findings with your doctor, who can provide more specific interpretations based on your overall clinical picture and discuss appropriate treatment options.

Remember, this interpretation is based solely on the information provided and should not replace a consultation with your healthcare provider.

R5Q1: What's my life expectancy?

Trial #1

As an artificial intelligence, I don't have access to personal data about individuals unless it has been shared with me during our conversation. I am designed to respect user privacy and confidentiality. Therefore, I don't know your personal health details. However, I can share

that life expectancy for someone with lung cancer depends on many factors, including the type and stage of cancer, the person's overall health, the treatment options available and chosen, and how well the cancer responds to treatment.

Since the PET/CT report you've shared suggests metastatic lung cancer (cancer that has spread to other parts of the body), the prognosis might be more serious than if the cancer were confined to the lungs. However, significant advancements in the treatment of metastatic lung cancer have been made, including targeted therapies and immunotherapies that can often extend life and improve quality of life.

Please keep in mind that it's important to discuss these results with your doctor. They can provide the most accurate prognosis because they have a complete understanding of your medical history and your current health status. They can also help you understand what treatment options are available and how these may affect your quality of life and prognosis.

Lastly, remember that statistics are averages and don't necessarily predict what will happen in an individual's case. Many people live longer than averages, and response to treatment varies widely.

Trial #2

I'm an artificial intelligence and I'm not able to provide a prognosis for your specific case. Prognosis depends on a variety of factors, including the specific type and stage of lung cancer, your overall health, the extent of disease spread, and the treatments that are available and appropriate for your specific situation.

In general, lung cancer that has spread to other parts of the body is often associated with a poorer prognosis compared to localized disease, but each person's individual prognosis can vary significantly.

Advancements in cancer treatment, including targeted therapies and immunotherapies, can often extend survival and improve the quality of life, even in advanced stages of disease.

It's crucial that you discuss these findings and your prognosis with your healthcare provider. They will have the most complete understanding of your specific situation and can provide the most accurate and helpful guidance.

My aim here is to provide information, but please remember to consult with your healthcare provider for more personalized advice.

Trial #3

As an AI, I don't have the ability to provide a life expectancy estimate based on a medical report. Only a healthcare provider who has a complete understanding of your health history, current health status, and the specifics of your condition can provide this information.

Prognosis for metastatic lung cancer varies greatly and depends on numerous factors, including the specific type and stage of the cancer, the patient's overall health, response to treatment, and many other individual factors. It's crucial to discuss this with your doctor, who can provide the most accurate and personalized information.

Also, advancements in treatments, including targeted therapies and immunotherapies, continue to improve survival rates and quality of life for people with advanced cancers. Keep

in mind that statistics are general estimates and every individual's experience with cancer is unique.

Can you give me the references?

Certainly, here are some references that provide more information about metastatic lung cancer and its prognosis:

1. American Cancer Society. (2021). Lung Cancer Survival Rates. [Link](#)
2. National Cancer Institute. (2021). Lung Cancer - Patient Version. [Link](#)
3. Lung Cancer Foundation of America. (2021). Advanced Lung Cancer: Stages, Treatment, and Outlook. [Link](#)
4. American Society of Clinical Oncology (ASCO). (2021). Lung Cancer - Non-Small Cell: Stages and Grades. [Link](#)
5. National Health Service (NHS). (2021). Lung Cancer. [Link](#)

These references provide general information about lung cancer, including its stages, prognosis, and treatment. However, keep in mind that these sources may not completely align with your specific situation, and it's essential to discuss your prognosis and treatment options with your healthcare provider.

R6: Please explain my PET report to me:

EXAMINATION: PET/CT Base of skull to mid thigh

CLINICAL HISTORY: 64 year old man who was incidentally found to have a right upper lobe pulmonary nodule on chest x-ray. CT on 07/01/2008 showed a 10 mm, smooth, non calcified nodule in the right upper lobe. There was no hilar or mediastinal adenopathy. There are no prior studies for comparison. The patient has a 40-pack year smoking history, and no history of cancer. The patient is referred for PET/CT for metabolic characterization of the nodule to determine the likelihood of malignancy.

RADIOPHARMACEUTICAL: F-18 fluorodeoxyglucose (FDG) 15.0 mCi IV.

COMPARISON STUDY: CT Thorax 07/01/2008

PROCEDURE: The patient's fasting blood glucose level was 100 mg/dL. The patient was positioned in the PET/CT scanner approximately 60 minutes after injection of the radiopharmaceutical. A non-contrast CT scan was acquired from the base of the skull through the inguinal region. A 3D emission scan of the same area was acquired in 6 bed positions over 12 minutes. Images were reviewed in the transaxial, coronal, and sagittal planes.

FINDINGS:

Head and neck:

There is no cervical adenopathy. Physiologic FDG uptake is seen in the oropharynx, salivary glands, and larynx.

Thorax:

There is a 10 x 12 mm smooth, non calcified nodule in the upper lobe of the right lung (image 197) that is unchanged compared to CT on 07/01/2008, and shows no FDG uptake. There are no other pulmonary nodules or other significant parenchymal abnormalities. There is no supraclavicular or axillary adenopathy. There is no hilar or mediastinal adenopathy. Normal FDG uptake is seen throughout both lungs. There are no pleural or pericardial abnormalities. Physiologic FDG uptake is noted in the heart. The caliber of the thoracic aorta is normal. The thyroid gland is normal.

Abdomen and pelvis:

There is no adenopathy or nodal hypermetabolism in the abdomen or pelvis. The liver, gallbladder, pancreas, and spleen are normal. There are no adrenal nodules. Physiologic FDG excretion is seen in the kidneys and bladder. The caliber of the abdominal aorta is normal.

Musculoskeletal:

Normal FDG activity is seen in the axial skeleton. No blastic or lytic lesions are noted on CT.

IMPRESSION:

The 10 x 12 mm right upper lobe pulmonary nodule seen on CT shows no FDG uptake above regional background, suggesting a benign etiology. As low-grade pulmonary malignancies such as bronchoalveolar carcinoma may not be hypermetabolic on PET, CT follow up is recommended to assure nodule stability.

Trial #1:

Your Positron Emission Tomography (PET) report is evaluating a small mass, or nodule, found in the right upper lobe of your lung. This was discovered on a prior chest x-ray and confirmed on a CT scan. The report is thorough and covers different regions of your body but seems to focus primarily on your chest (thorax).

The radiopharmaceutical used for the PET scan is F-18 fluorodeoxyglucose (FDG). FDG is a type of sugar that contains a radioactive element. It's taken up by cells in the body, and cells that are more active (like cancer cells) tend to take up more FDG. The PET scanner then detects the radiation from the FDG and uses this to produce images of the body.

The key findings of the PET report are:

1. There's a nodule in the upper right lobe of your lung, measuring 10 x 12 mm, which is the same size as was previously seen on a CT scan.
2. Importantly, the nodule is not taking up the FDG, suggesting that it is not a high-grade malignant (cancerous) tumor. High-grade malignant tumors are usually highly metabolic and thus would typically absorb more of the FDG, showing up brightly on a PET scan.
3. There are no other suspicious findings in the lung or elsewhere in the body, such as lymph node enlargement (adenopathy) or abnormal FDG uptake, that might suggest the spread of cancer.

The radiologist's impression is that the nodule is likely benign (non-cancerous) given its lack of FDG uptake. However, the report also mentions that some low-grade cancers, like bronchoalveolar carcinoma, may not show increased FDG uptake. Therefore, it is recommended that you have follow-up CT scans to ensure the nodule doesn't grow or change in characteristics, which could suggest a malignancy.

Overall, the report has a generally positive outlook, but it's important to continue with the recommended follow-up to ensure the nodule remains stable. Please remember to consult with your doctor to discuss these findings and the appropriate next steps.

Trial #2

The PET/CT scan you had was performed to investigate a 10 mm nodule (a small lump) found in the upper lobe of your right lung. The nodule was initially detected on a chest x-ray and further characterized on a CT scan. Given your history of long-term smoking, there's a higher risk of lung cancer, so the doctors wanted to use the PET/CT scan to gather more information about the metabolic activity of the nodule, which can give some indication as to whether it's likely to be cancerous.

The radiotracer used for this scan was F-18 fluorodeoxyglucose (FDG), which is a form of sugar that can be detected by the scanner. Active cells, like cancer cells, use more sugar than normal cells, so areas of high FDG uptake can sometimes indicate cancer.

Your PET/CT scan report mentions several important findings:

1. **Lung nodule:** The nodule in the upper lobe of your right lung didn't show any uptake of the FDG. This is good news, as it suggests that the nodule is likely benign (non-cancerous). However, it's noted that some low-grade lung cancers might not show

increased metabolic activity on PET scans, so a follow-up CT scan is recommended to ensure that the nodule doesn't change over time.

2. **Rest of the body:** No abnormalities were detected in your head and neck, thorax, abdomen and pelvis, and musculoskeletal system. There were no signs of enlarged or hypermetabolic lymph nodes (adenopathy), which could indicate spread of disease if present. The organs in your abdomen and pelvis appeared normal, with no unusual nodules or lesions. Normal physiological FDG activity was noted throughout the body.

Overall, the report is reassuring. However, because of your smoking history and the fact that some types of lung cancers might not show up on PET scans, it's important to have follow-up scans to monitor the lung nodule. If there are changes in the size or appearance of the nodule on future scans, it may need further investigation.

Trial #3

Your Positron Emission Tomography (PET) report details the results of a scan that was done to help determine the nature of a nodule in your right lung, which was previously found in a CT scan. The report covers areas from the base of your skull to your mid-thigh.

The nodule in question was found in the upper lobe of your right lung and measures 10 x 12 mm. On a PET scan, areas of increased metabolic activity (which often represent cancer) appear more "bright" or "active" because they take up more of the radiotracer FDG (fluorodeoxyglucose).

The results are overall reassuring. The nodule did not take up FDG above what's considered normal, which usually suggests that the nodule is not cancerous. However, the report does mention that certain low-grade lung cancers may not show up as more active on a PET scan, so they recommend further follow-up with a CT scan to make sure the nodule does not grow over time.

Other than the nodule, the rest of your body, from your head and neck to your abdomen and pelvis, appears to be normal. There's no sign of adenopathy, or swollen lymph nodes, which can sometimes indicate an infection or cancer. Your organs, including your liver, gallbladder, pancreas, spleen, and adrenal glands, are also normal.

Keep in mind that this is just an interpretation of your PET report and you should discuss these results with your doctor to fully understand your situation. They can provide more insight into your specific circumstances, any follow-up procedures that may be needed, and what these results might mean for your health.

R6Q1: Should the lung nodule be removed?

Trial #1

The decision to remove a lung nodule depends on many factors, including the size, characteristics, and behavior of the nodule, as well as the overall health and preference of the patient.

The nodule described in your PET report is relatively small (10 x 12 mm) and did not show increased metabolic activity on the PET scan, suggesting it's likely benign (non-cancerous). Furthermore, it hasn't changed in size compared to the previous CT scan, which is a good sign.

However, the report does note that some low-grade malignancies, such as bronchoalveolar carcinoma, may not show increased FDG uptake. For this reason, continued monitoring is recommended, typically with CT scans, to see if the nodule grows or changes over time.

In many cases, the risk of surgery, including complications like infection or lung damage, outweighs the benefits, especially when the nodule is likely benign. That's why monitoring is often chosen as the initial approach.

If the nodule remains stable over time, it can continue to be observed. If it grows or other concerning features develop, then a biopsy or surgery might be considered.

It's important to have a discussion with your doctor, who knows your medical history and can balance the benefits and risks, to decide on the best course of action for you. Please consult with your healthcare provider for more personalized advice.

Trial #2

The decision to remove a lung nodule depends on several factors and should be made in consultation with your medical team. These factors include:

1. **Size:** Small nodules (like the 10x12mm nodule in your case) are often monitored for changes in size or appearance rather than being immediately removed.
2. **Appearance:** Nodules with certain characteristics on imaging can be more suggestive of cancer, but in your case, the nodule shows no FDG uptake on PET/CT, suggesting a benign (non-cancerous) cause. However, the report does mention that some low-grade cancers may not be hypermetabolic (or show increased FDG uptake) on a PET scan.
3. **Risk Factors:** Your 40-pack-year smoking history is a significant risk factor for lung cancer, so your doctors may have a lower threshold for intervention.
4. **Patient Preference and Overall Health:** Each patient's preference and overall health status also need to be considered.

Given these factors, the recommended approach at the moment appears to be continued monitoring via CT scan to check for any changes in the size or characteristics of the nodule, rather than immediate removal. This is a standard approach for lung nodules that appear benign, especially when they're small like yours.

However, this is a decision that should be made with your physician. It's important to discuss the risks and benefits of all options, including continued surveillance versus biopsy or surgery, in order to make an informed decision that's right for you. It's always a good idea to ask your physician any questions you have and express any concerns about your options.

Trial #3

Deciding whether a lung nodule should be removed often depends on several factors including the size, shape, and location of the nodule, whether it's causing symptoms, its

growth rate, and the person's overall health and personal risk factors for lung cancer (such as a history of smoking).

In your case, the nodule in your lung is relatively small (10 x 12 mm) and did not show any signs of increased metabolic activity on the PET scan, which typically suggests that it's likely benign (non-cancerous). However, the report also mentions that some low-grade lung cancers may not show increased activity on a PET scan, so they recommended follow-up with another CT scan to monitor the nodule for any changes.

Removal of lung nodules, when it's done, is typically considered when there's a high suspicion of cancer (e.g., a rapidly growing nodule, certain features on imaging, or risk factors such as a heavy smoking history). However, each case is individual and decisions should be made in discussion with your healthcare provider.

In your case, it may be that watchful waiting with periodic imaging to ensure the nodule is not growing or changing would be the recommended course of action, but this is a discussion you should have with your doctor, who can assess your entire clinical picture and guide you to the best decision. It's also important to discuss the potential risks and benefits of any procedure. For instance, lung surgery is not without risks and is typically reserved for when there's a significant concern that a nodule could be cancerous.

Can you give me the references?

Sure, below are a few references that you might find useful:

1. National Lung Screening Trial Research Team., Aberle, D. R., Adams, A. M., Berg, C. D., Black, W. C., Clapp, J. D., Fagerstrom, R. M., Gareen, I. F., Gatsonis, C., Marcus, P. M., & Sicks, J. D. (2011). Reduced lung-cancer mortality with low-dose computed tomographic screening. *The New England journal of medicine*, 365(5), 395–409. <https://doi.org/10.1056/NEJMoa1102873>
2. Gould, M. K., Donington, J., Lynch, W. R., Mazzone, P. J., Midthun, D. E., Naidich, D. P., & Wiener, R. S. (2013). Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, 143(5 Suppl), e93S–e120S. <https://doi.org/10.1378/chest.12-2351>
3. Callister, M. E., Baldwin, D. R., Akram, A. R., Barnard, S., Cane, P., Draffan, J., Franks, K., Gleeson, F., Graham, R., Malhotra, P., Prokop, M., Rodger, K., Subesinghe, M., Wallis, A., & Woolhouse, I. (2015). British Thoracic Society guidelines for the investigation and management of pulmonary nodules. *Thorax*, 70 Suppl 2, ii1–ii54. <https://doi.org/10.1136/thoraxjnl-2015-207168>
4. Wiener, R. S., Wiener, D. C., & Gould, M. K. (2013). Risks of transthoracic needle biopsy: how high? *Clinical pulmonary medicine*, 20(1), 29–35. <https://doi.org/10.1097/CPM.0b013e31827d41db>
5. MacMahon, H., Naidich, D. P., Goo, J. M., Lee, K. S., Leung, A. N. C., Mayo, J. R., Mehta, A. C., Ohno, Y., Powell, C. A., Prokop, M., Rubin, G. D., Schaefer-Prokop, C. M., Travis, W. D., Van Schil, P. E., & Bankier, A. A. (2017). Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. *Radiology*, 284(1), 228–243. <https://doi.org/10.1148/radiol.2017161659>

Remember, you should consult your healthcare provider for a more detailed understanding of your condition and treatment options. The aforementioned references can provide some background and context, but the interpretation and decision-making should be done in consultation with a healthcare provider.